Brief: Pluristem Therapeutics - U.S. FDA Approves Cost Recovery For PLX-PAD

Pluri

16/10/2018 12:06

Oct 16 (Reuters) - Pluristem Therapeutics Inc  PSTI.O :
    * U.S. FDA APPROVES COST RECOVERY FOR PLX-PAD UNDER EXPANDED
ACCESS PROGRAM IN THE TREATMENT OF CRITICAL LIMB ISCHEMIA
    * U.S. FDA APPROVES COST RECOVERY FOR PLX-PAD UNDER EXPANDED
ACCESS PROGRAM IN THE TREATMENT OF CRITICAL LIMB ISCHEMIA
    * PLURISTEM THERAPEUTICS INC - WIDETRIAL WILL PURCHASE
PLX-PAD
CELL PRODUCTS FROM PLURISTEM
    * PLURISTEM THERAPEUTICS INC - PROGRAM ALLOWS FOR COLLECTION
OF
REAL-WORLD DATA CONCURRENT WITH PHASE 3 STUDY
    * PLURISTEM - PROGRAM MAKES INVESTIGATIONAL TREATMENT
AVAILABLE TO
CLI PATIENTS UNSUITABLE FOR INCLUSION IN ONGOING MULTINATIONAL
PHASE 3 CLINICAL STUDY
    * PLURISTEM - AGREEMENT TO INITIATE FDA-CLEARED EAP FOR
PLURISTEM'S CELL THERAPY PRODUCT, PLX-PAD, FOR TREATMENT OF CLI

Source text for Eikon:  ID:nGNX9XfpHw 
Further company coverage:  PSTI.O 

 ((Reuters.Briefs@thomsonreuters.com;))